Company / Current Assets
GT Biopharma, Inc. Current Assets History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$5.7M
FY2020
5-year range
$49.0K / $5.7M
FY2016-FY2020
Trend
+882.8%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets changed +883% YoY in FY2020, a notable deviation from the 7-year average annual change of +361%.
Based on SEC 10-K filings.
$6M in FY2020 with a 5-year CAGR of +45.0%.
Improved from $49,000 to $6M over the past 4 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +114.2%
- 5-Year CAGR
- +45.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +45.0%, indicating consistent growth.
- In FY2020, current assets increased 882.8% year-over-year.
- Lowest current assets in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $5.7M | +882.8% |
| FY2017 | $576.0K | +1075.5% |
| FY2016 | $49.0K | -94.4% |
| FY2015 | $882.0K | +0.0% |
| FY2014 | $882.0K | +605.6% |
| FY2013 | $125.0K | -38.1% |
| FY2012 | $202.0K | +94.2% |
| FY2011 | $104.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026